Loading stock data…
ALT
$2.82+0.22 (+8.46%)
Market ClosedLast close May 1
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Altimmune, Inc. in the Healthcare sector is trading at $2.82. The stock is currently near its 52-week low of $2.56, remaining 30.0% below its 200-day moving average. Technical signals show neutral RSI of 38 and bearish MACD signal, explaining why ALT maintains its current current market pressure. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 38) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.82
Potential Upside
5%
Whystock Fair Value$2.96
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Buy
Mean target$18.15+543.6%
Range$2.50 – $28.00
Fundamentals
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$391.63M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.34
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-39.17%
Volume
Today's trading volume
4.83M
Recent News
Here is Why Altimmune Inc. (ALT) Appears to be an Attractive Penny Stock
Altimmune Inc. (NASDAQ:ALT) is one of the 10 most shorted penny stocks to buy. On March 19, Truist began coverage of Altimmune Inc. (NASDAQ:ALT) with a $12 price target, leading to a whopping 315% upside potential at the prevailing level. The firm also assigned a Buy rating to the stock. According to Truist, Altimmune’s primary […]
Altimmune Catalysts: 2026 Data Readouts and Financing Risks
ALT's 2026 hinges on pemvidutide, with key readouts, a phase III start, and funding strategy set to shape investor sentiment.
ALT Stock: What Pemvidutide Means for MASH, AUD and ALD
Altimmune bets big on pemvidutide across MASH, AUD and ALD, but with one drug driving value, upcoming trials could make or break the story.
Is Altimmune a Buy Before Phase III MASH Starts in 2026?
ALT heads into a high-stakes 2026 as pemvidutide drives key phase III and mid-stage catalysts that could reshape its valuation-or risk setbacks.
Independent Non-Executive Director of Altitude Group Picks Up 100% More Stock
Even if it's not a huge purchase, we think it was good to see that Robert Charles Wigley, the Independent Non-Executive...